<DOC>
	<DOCNO>NCT01684163</DOCNO>
	<brief_summary>GLYX-13 NMDA receptor glycine site partial agonist study subject major depressive disorder ( depression ) respond inadequately another antidepressant drug current episode . This trial ass effect GLYX-13 depression add another antidepressant drug patient already take .</brief_summary>
	<brief_title>Efficacy Safety GLYX-13 Subjects With Inadequate/Partial Response Antidepressants</brief_title>
	<detailed_description>To evaluate mean difference Hamilton Depression Rating Scale 17 ( HDRS-17 ) score combine GLYX-13 mean change versus placebo group mean change end 6 week randomize withdrawal phase ( predose baseline score - score end randomize withdrawal period ) .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Male female subject Aged 18 65 year Meets DSMIVTR ) criteria major depressive disorder ( MDD ) Current episode last ≥ 8 week Screening inadequate response approve antidepressant agent ( ) administer adequate dose duration current episode Taking antidepressant agent currently take SSRI SNRI HDRS17 score ≥ 18 screen predose baseline Female subject childbearing potential negative serum pregnancy test prior entry study practice adequate method birth control plan become pregnant course study . Clinical laboratory value &lt; 2 time upper limit normal ( ULN ) deem clinically significant per investigator Naurex medical monitor Ability understand requirement study , provide write informed consent , abide study restriction , agree return require assessment Based investigator Naurex medical monitor 's clinical judgment , subject eat disorder , obsessive compulsive disorder ( OCD ) , panic disorder , posttraumatic stress disorder ( PTSD ) , generalize anxiety disorder secondary major depressive episode ( MDEs ) permit . Axis I diagnosis delirium , dementia , dysthymia , amnestic cognitive disorder , schizophrenia psychotic disorder , bipolar I II disorder , eat disorder ( anorexia bulimia nervosa ) , obsessivecompulsive disorder , panic disorder , acute stress disorder , agoraphobia , social phobia , attentiondeficit hyperactivity disorder ( ADHD ) , PTSD A clinically significant current Axis II diagnosis borderline , antisocial , paranoid , schizoid , schizotypal , histrionic personality disorder Experiencing hallucination , delusion , psychotic symptomatology current episode ; lifetime history psychosis Huntington 's , Parkinson 's , Alzheimer 's , Multiple Sclerosis , history seizure stroke Currently hospitalize reside inpatient facility study participation Substance abuse within last 12 month Women plan become pregnant course study Allergy intolerance current antidepressant current medication Participation clinical trial investigational product device within 30 day enrollment trial exception GLYX13C201 . Positive screen drug abuse Have receive electroconvulsive therapy , transcranial magnetic stimulation ( TMS ) , vagal nerve stimulation ( VNS ) current depressive episode Pose current ( past 6 month ) suicide risk base administration C SSRS investigator 's clinical judgment Human immunodeficiency virus ( HIV ) infection ( base HIV1 &amp; HIV2 antibody screen ) ongoing infectious disease Females currently pregnant plan become pregnant course study Dextromethorphan tramadol since serotonin uptake inhibitor History allergy , sensitivity , intolerance NmethylDaspartate receptor [ NMDAR ] ligand</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>MDD</keyword>
	<keyword>GLYX-13</keyword>
	<keyword>HDRS-17</keyword>
	<keyword>HAMD-17</keyword>
</DOC>